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Abstract
The β-thalassemia is a hereditary blood disorders, characterized by reduced or 
absent synthesis of the hemoglobin beta chain that cause microcytic hypochromic 
anemia. An early diagnosis, economical test, awareness programs and prenatal 
screening will be a milestone for the eradication of this genetic disorder and to 
reduce burden of the health sector of a country subsequently the economics. 
Initially, the diagnosis of β-thalassemia depends on the hematological tests with 
red cell indices that disclosed the microcytic hypochromic anemia.Hemoglobin 
analysis shows the abnormal peripheral blood smear with nucleated red blood cells, 
and reduced amounts of hemoglobin A (HbA). In severe anemia, the hemoglobin 
analysis by HPLC reveals decreased quantities of HbA and increased the level of 
hemoglobin F (HbF).The decrease level of MCV and MCH are also associated with 
β-thalassemia. There are various different molecular techniques such as ARMS 
PCR, allele-specific PCR, Gap PCR, denaturing gradient gel electrophoresis, 
reverse dot blotting, DGGE, SSCP, HRM, MLPA, sequencing technology and 
microarray available to identify the globin chain gene mutations. These molecular 
techniques can be clustered for detection by mutation types and alteration in gene 
sequences.
Keywords: β-thalassemia, Microcytic Hypochromic Anemia, HPLC, Mutation, 
Molecular techniques
1. Introduction
There are many tests available for the diagnosis of thalassemia and hemoglo-
binopathies. However, diagnosis of these conditions that is sufficiently accurate 
for most of the clinical conditions can usually be established from complete family 
history (pedigree analysis) and a complete clinical and hematological examination 
of the patient and their family members.
Generally, doctors everywhere in the world diagnose thalassemia using blood 
tests which include a complete blood count and special tests for hemoglobin 
abnormalities. Initially, the primary screening of the thalassemia depends on the 
complete blood count (CBC), detection of carriers is done by hematological tests 
with red cell indices and microcytic hypochromic with mild anemia. The high 
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performance liquid chromatography (HPLC) or capillary zone electrophoresis is 
used for the identification of qualitative and quantitative assessment of hemoglobin 
(Hb) components. HbA2 test is the most significant identification test for β thalas-
semia minor, but it can be vary by the presence of defective δ-thalassemia. In earlier 
days various molecular techniques e.g. amplification refractory mutation specific-
polymerase chain reaction ((ARMS-PCR), GAP PCR have been used for the detec-
tion of mutations in β- and α-thalassemia, which may help in the prenatal diagnosis 
of thalassemia hemoglobinopathy in a limited time. Recently the evolution of 
Next- Generation Sequencing (NGS) has taken an important place for the diagnosis 
of thalassemia as a confirmatory diagnostic test. The NGS has been introduced for 
the characterization of both α- and β-thalassemia genes. It gives an accurate diag-
nosis of thalassemia, although NGS predicts much higher carrier frequencies. The 
molecular analysis is fundamental to foresee the severe blood transfusion-depen-
dent thalassemia cases to the mild or no blood transfusion. The prenatal diagnosis 
based on DNA by amniocentesis and chorionic villus sampling (CVS) is equivalent 
required to detect the genetic abnormalities of the foetus as per expertise. Now a 
day’s NIPT (Noninvasive prenatal testing) is a technique to identify the genetic 
abnormalities of the foetus. This testing examines the small remains of foetus DNA 
that are circulating in a pregnant mother’s blood. An appropriate lab conclusion is 
urgent for describing the various types of thalassemia hemoglobinopathy with a 
significant association for prevention and treatment.
This chapter will explain all of these tests, the information of which will be 
useful for those who are working and interested in the diagnosis of thalassemia 
hemoglobinopathy.
2. Diagnostic strategies for thalassemia
In many diagnostic labs, the diagnostic strategies have been established for the 
diagnosis of thalassemia from the simple PCR to NGS for the detection of common, 
less common and rare thalassemia mutations [1]. Although there are lots of PCR 
technologies available in the laboratory but most of the diagnostics labs are using 
the simple and robust technique on allele- specific oligonucleotide hybridization or 
allele-specific priming, e.g. reverse dot-blotting or ARMS-PCR for the identification 
of the beta-thalassemia carrier [2]. This approach helps in identifying the common 
and less common mutations in 90% of cases. The rare mutations will be identifying 
by secondary screening. The mutation which remains unidentified after these two 
screenings will be then characterized by DNA sequencing [3]. DNA sequencing is 
a technique used to identify the specific arrangement of nucleotide bases (A, C, G, 
and T) in a DNA. The DNA carries the information a cell needs to collect protein 
and RNA molecule. DNA grouping data is imperative to researchers examining 
the elements of qualities. DNA sequence information is mandatory to researchers 
examining the functions of genes [4].
However worldwide laboratories, it has been noticed that a result of the migra-
tion of the natives with different ethnicity has led to increasing the variety of 
hemoglobinopathy and thalassemia mutations that need to be identified. Because of 
migration the genetic makeup of the population has mixed, these Hb variations are 
presently seen everywhere. Thus, the compound heterozygous conditions (Hb D–β 
thalassemia, Hb E–β thalassemia and Hb Sβ thalassemia) are seen in various places 
[5]. Molecular indicative research centers in such nations should have the special-
ized skill, equipment, and diagnostic approach to distinguish an enormous variety 
of mutations rapidly for prenatal diagnosis, and these labs use DNA sequencing as 
the principle evaluating strategy for the diagnosis of β-thalassemia point mutations.
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The flow chart shows the step wise diagnostic model for thalassemia (Figure 1). 
The hematological and biochemical tests such as complete blood count (CBC) and 
Hb type identification were performed for suspected anemic patients. The altered 
or abnormal biochemical findings will be further confirmed by molecular analysis. 
The Allele-specific oligonucleotide (ASO), reverse dot-blot (RDB), ARMS-PCR, 
RE-PCR, Gap-PCR, MLPA and sequencing will be performed for known and 
unknown mutations. Finally prenatal will be done followed by genetic counseling in 
the affected family.
The government of the country should make various screening and diagnosis 
mandatory for the eradication of thalassemia. They are indicated as under men-









Premarriage screening should be implemented to detect β thalassemia carriers 
and hemoglobinopathies such as sickle cell trait. In developing country, it is not 
frequently acceptable because of social stigma and reasons in the general public. 
Figure 1. 
Flow chart explain the diagnosis of thalassemia from primary to secondary screening.
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The premarriage screening should be possible in universities and colleges, schools, 
or public places such as theater, shopping mall etc. Earlier it was performed in 
where the predominance of thalassemia is high. But nowadays due to the mixing 
up of the gene pool this screening is recommended in all colleges where students 
are of marriageable age. Our lab has performed this screening in the Tharu tribal 
area of the Kheri Lakhimpur, Uttar Pradesh, India. We have collected more than 
700 samples from the college and carrier screening of sickle cell disease has been 
performed. It is a belt of HBS [7].
2.2 Antenatal screening
In antenatal screening irrespective of gestational age of all pregnant women 
should be screened for carrier status of thalassemia and hemoglobinopathies. 
The spouse of the affected female should be test for mutation such as α-, β thal-
assemia and hemoglobinopathies (HbS trait, Hb E trait, Hb D trait etc.). The 
Prenatal diagnosis have to be encouraged if the foetus is in danger for the having 
thalassemia mutations e.g. α-, β thalassemia and hemoglobinopathies (HbS trait, 
Hb E trait, Hb D trait etc.). If the couple found positive for thalassemia dur-
ing antenatal screening they can decide for prenatal diagnosis and subsequent 
pregnancy [8–11].
2.3 Preconception screening
While troublesome circumstances are in the developing country like India, 
this ought to be done but mostly females frequently do not enroll in antenatal 
centres before 12 weeks of gestation. A similar methodology with respect to 
antenatal screening ought to be followed. The preconception screening is impor-
tant for all couples coming to IVF in infertility clinics. If the female is a thalas-
semia carrier then her husband or sperm donor should be screened and vice 
versa [8–11].
2.4 Neonatal screening
Infant screening is mainly suggested in haemoglobinopathies such as sickle cell 
diseases, prevalent in tribal and urban populations. If possible, neonatal screening 
has to be implemented universally where infants are at high-risk for homozygous 
β-thalassemia and all instances of HbS–β thalassemia. This methodology will miss a 
couple of instances of sickle β-thalassemia when the mother is a β-thalassemia car-
rier and the father is a carrier of HbS. All babies with significant hemoglobinopathy 
should be re-tested using molecular technology to confirm the diagnosis within 
three months after birth [8–11].
2.5 Preoperative/pre-anesthesia screening
Preoperative/pre-anesthesia screening of patients is preventive measure where 
the prevalence of HbS is high. As the presence of sickle hemoglobin might interfere 
during preoperative and postoperative procedures [8–11].
2.6 Genetic counseling
Genetic counseling should be given by an expert to affected thalassemia fami-
lies. The advice can likewise be given by a trained genetic counselor, a hematologist, 
or a pediatrician [8–11].
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3. Screening methods for thalassemia
3.1 Hematological screening
The primary screening of thalassemia is based on (MCV, MCH) values, Hb A2 
levels, and F levels by automated blood analyzer, Hb electrophoresis and HPLC, 
respectively. The secondary screening encompasses further hematological studies 
to detect suspected variant such as sickle solubility, iron levels and heat instability 
tests. The complete blood count (CBC) measures the exact amount of hemoglobin 
and different types of blood cells. As it is clear that when there are mutations in the 
genes which are responsible for the hemoglobin synthesis that can lead to hemo-
globinopathies. It can be further categorized based on of the type of mutations on 
the globin genes (α, β, δβ) and abnormal structural variants such as Hb Lepore and 
Hb E. These discrepancies in the mutations on the globin chains led to the different 
phenotypes of thalassemia. When there is a substantial increase of HbF in adults 
caused by the γ-globin chains synthesis after birth without any important clinical or 
hematological manifestations, this condition is known as Hereditary Persistence of 
Foetal Hemoglobin (HPFH) [12].
The variations from the typical hematological phenotypes of β-thalassemia 
carrier include:
• Decrease level of MCV and MCH with marginal or normal levels of Hb 
A2 when person must consider α -thalassemia, heterozygosity for mild 
β-thalassemia mutations, iron deficiency, heterozygosity for eγδβ-thalassemia.
• Normal/Borderline MCV and MCH levels with higher Hb A2 when person 
must deliberate co-inheritance of alpha and beta-thalassemia.
• Normal Hb A2 with Normal or decreased red cell indices but raised Hb F level 
when person should consider heterozygous δβ -thalassemia or HPFH.
• The deranged hematological and biochemical value after primary and second-
ary screening is confirmed by molecular analysis.
Red cell distribution width (RDW) test is an estimation of the range in the 
volume and size of the RBC (Red blood cell, Erythrocytes). The RBC move oxygen 
from the lungs to each cell in the body which helps in normal development. If the 
RBC’s are bigger than the normal size, it could show a health problem. The RDW 
test is normally used to investigate anemia. It is a condition wherein the RBC cannot 
carry sufficient oxygen to the body. The RDW test may likewise be utilized to diag-
nose thalassemia [13]. This change in RDW is very remarkable in thalassemia from 
HbH sickness to thalassemia minor [14]. In thalassemia, RBC count is increased 
with microcytic anemia in compared to iron deficiency anemia (IDA) and iron 
deficiency where RBC count is relatively decreased. That’s why in any hemoglobin 
disorder RBC count and RDW level should not be considered as only evaluating 
methods.
3.2 Biochemical screening
As per the International Committee for Standardization in Hematology (ICSH) 
in 1978, has recommended three kinds of lab tests for the diagnosis of thalassemia 
and hemoglobinopathies [15]. In that rule, the screening research facility ought to 
have the option to perform the alkaline electrophoresis. The reference lab approved 
Hemodynamics
6
by ICSH needed to perform challenging tests like globin electrophoresis and citrate 
agar electrophoresis. It is necessary to have manual strides all through hemoglobin 
investigation from reagent availability, electrophoresis, and information examina-
tion, and accordingly, the experience of the research centre proficient was a key 
to fruitful recognizable proof. Late improvement of lab strategies and expanded 
information on hemoglobinopathy and thalassemia has determined the distribu-
tion of refreshed rules [16]. The British Committee for Standards in Hematology 
suggests possible recognizable proof of hemoglobins on at least two procedures and 
gets conclusive ID as that dependent on DNA examination, protein sequencing or 
mass spectrometry.
Electrophoresis is a strategy used to isolate atoms or mixtures dependent on 
their movement design in a gel and electrical field. It is more commonly utilized in 
diagnostics labs for protein electrophoresis and the separation of some isoenzymes. 
Manual planning of gel and electrophoresis is infrequently utilized in evolved 
nations as further developed and computerized methods, for example, narrow 
electrophoresis are accessible.
In early long stretches of finding cellulose acetic acid derivation electrophoresis 
is an agent custom electrophoresis strategy. It gives distinguishing proof of Hb A, F, 
S/G/D, C/E, and H and different variations [16].
High Performance fluid chromatography (HPLC) is a technique in which iso-
late mixtures of atoms dependent on their substance qualities. Numerous division 
standards like affinity, segment and size are accessible; for hemoglobin, molecule 
exchange chromatography is proficient and frequently utilized. The technique can 
be additionally physically worked, yet as of late completely mechanized frameworks 
are accessible. Those frameworks might be devoted to hemoglobin examination for 
haemoglobinopathies and thalassemia (Figure 2).
HPLC is useful for the finding of β-thalassemia carrier since that HbA2 can be 
correctly quantitated [16]. Similar other HPLC methods, a wary control of insight-
ful conditions like segment temperature, stream rate, and backup conditions are 
important.
Mass spectrometry is a procedure to recognize molecules dependent on their 
mass (sub-atomic weight) to charge proportion. In this procedure, the molecule 
of the interest required minimal specific binding reagents. The simple analytical 
norm allows less interfering but rather more precise detection. In this technique, 
the examination of hemoglobin is not easy as it required specialized ability for the 
investigation of proteins and costly instruments. Other than detecting of hemoglo-
bin based on the intact molecular weight, it can likewise examine the amino acids 
sequence. Mass spectrometry is helpful tool for the detection of new confirmation 
and DNA sequencing variations [17].
3.3 Advance molecular techniques for the characterization of thalassemia
There are various different molecular techniques available to identify the globin 
chain gene mutations. These molecular techniques can be clustered for detection by 
mutation types such as structural variations (Gene deletion, duplication, or triplica-
tion) and alteration in gene sequences (Insertion, substitution, or short insertion/
deletions) [18, 19]. Over 90% of α-thalassemia patients are caused by gene dele-
tion. Approximate 10% of the α-thalassemia cases are due to the alteration in the 
gene sequence such as single nucleotide insertion, deletion or substitution [20]. 
The α-globin gene group encode identical protein which consists of exceptionally 
homologous genes as well as 2 HBA genes. The gene deletions in α-thalassemia are 
mainly cause due to imbalanced crossing over between these homologous regions 
during meiosis [21]. The most well-known deletion of 3.7 kb and 4.2 kb has been 
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reported [22]. More than 90% of β-thalassemia cases are caused by the alteration in 
the gene sequence as compared to α-thalassemia. Approximately, 280 gene sequence 
alterations are related with β-thalassemia in which some mutations are caused by 
the deletion of gene including the HBB gene [22].
Gap polymerase chain reaction (PCR) technique is mainly used for the detection 
of deletion. The southern blotting may be used for unknown deletions with the help 
of using probes. The MLPA (multiplex ligation-dependent probe amplification) 
technique can identify both known and unknown deletions. It is commonly used 
in diagnostics labs for its highly sensitive and is easy to use. Common mutation or 
alteration in gene sequences can be detected by using techniques such as amplifica-
tion refractory mutation specific (ARMS) PCR, allele-specific PCR, denaturing 
gradient gel electrophoresis, reverse dot blotting, DGGE, SSCP, HRM (High resolu-
tion melting), sequencing technology and microarray in a cost-effective manner.
Allele-specific oligonucleotide (ASO) hybridization and reverse dot-blot 
(RDB) techniques are used for the detection of known mutations. In this tech-
nique, the PCR products (amplified target DNA sequences) are hybridize with two 
Figure 2. 
HPLC of various types of haemoglobinopathies and thalassemia; (a) Normal hemoglobin (Hb);  
(b) β-thalassemia trait with A2 fraction on 5.8%; (c) and (d) compound heterozygous HbS and β-thalassemia 
trait (Nigam et al., 2020).
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oligonucleotide probes; one complementary to mutant sequence and the other to a 
normal sequence. The normal probes hybridized with normal individuals [23, 24]. 
The ASO’s vary from one another by the changes in a single nucleotide. The analysis 
of the change in a single nucleotide in DNA using hybridization with ASO probes 
that have been bound to a nylon membrane in the form of the dot after restriction 
endonuclease digestion and electrophoresis [23, 25–26]. The ASO probes are specific 
and complementary for the several alleles, to detect known mutation or single nucle-
otide polymorphism. This dot blot technique is used for one or two major mutations 
[27]. This was surprised by the development of the reverse dot-blotting technique, 
in which, the panel of mutation-specific probes is hybridized with amplified DNA, 
fixed to a nylon membrane. This method is viable with the ideal procedure for 
screening β-thalassemia mutations, using a panel of common known mutations for 
the primary screening and a panel of uncommon for the second screening [28].
Primer Specific Amplification– amplification refractory mutation spe-
cific (ARMS) PCR is the most commonly used technique for the detection of 
β-thalassemia mutations [29, 30]. This technique is a simple, quick screening assay; 
does not require the latest technology [30]. The ARMS primers have been made for 
the detection of common mutations of β-thalassemia [31]. In various countries like 
India and Pakistan, this technique quit well-known for screening and prenatal diag-
nosis due to its quick and low cost [32, 33]. The ARMS PCR is able to detect multiple 
known mutations in a single assay [29, 34, 35]. It is also identified the change in 
target DNA is heterozygous or homozygous. With the help of ARMS primers (com-
mon forward primer and two reverse one mutant and other to the normal primer 
sequence), ARMS PCR is differentiated homozygote or heterozygote.
Recently, ARMS PCR technology has been improved for the detection of both 
normal and altered alleles with internal positive control are detected in a single 
tube assay [35], referred to as tetra primer ARMS-PCR. Two pairs of primers are 
used in tetra, ARMS-PCR in which one pair of primers for flanking regions and 
other pair primers are complementary to different strands. These primers amplify 
the two different bases that are located in a single position of the globin gene. The 
different alleles (mutant and wild type) can be detected on an agarose gel based on 
their sizes (Figure 3). This ARMS PCR technique has been useful in the diagnosis 
of β-thalassemia mutations. Multiplex ARMS PCR can be screened for more than 
one mutation a single reaction by multiplexing the ARMS primers attached with a 
common primer [36].
Restriction enzyme PCR (RE-PCR)/restriction fragment length polymor-
phism (RFLP) has had a restricted diagnostic role due to few β-thalassemia muta-
tions restriction sites. Even though its use can be enlarged by the artificial formation 
of a restriction that includes the target mutation [37]. The fundamental use of 
RE-PCR has been for the examination of β-globin gene haplotypes to define the 
origin of mutations in the globin gene in various ethnic groups [38].
The target genomic DNA containing the mutation is amplified by PCR with the 
help of specific primers. The PCR products are digested by a specific restriction 
enzyme. The digested PCR products are separated on the agarose gel. The digested 
PCR products are separated according to their molecular weight (size). Based 
on restriction site (presence or absence) is determine the size or pattern of PCR 
products. This RE analysis is simple, relatively economical, and powerful prompt-
ing unequivocal outcomes; the RE-PCR-based technique is a precious molecular 
diagnostic tool. Be that as it may, it is restricted in its application as just an extent of 
the alpha-thalassemia, β-thalassemia mutation, and hemoglobin variations, natu-
rally generate restriction sites [26, 39].
Gap-PCR is a rapid, simple and non-radioactive technique that identified the 
deletions of globin gene. Gap-PCR amplifies the deleted DNA sequence in target 
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DNA by using the flanking primers for this region. This flanking primer pairs are 
making a unique PCR product, smaller for mutant sequence as compared to wild 
type sequence [40]. In alpha-thalassaemia mostly mutation are deletion types e.g. 
-α3.7, −α4.2 deletion, HbLepore and HPFH deletion etc. [41, 42]. In Asian Indians, 
619 bp deletion is found in β-thalassaemia. The limitation of Gap-PCR technique is 
that the deletion endpoints must be known for primers designing.
Denaturing gradient gel electrophoresis (DGGE) and single-stranded 
conformation polymorphism (SSCP) are used for the screening of the unknown 
mutations. The DGGE technique allows the DNA fragments differing by single 
nucleotide base change according to its melting characteristics [43, 44]. In SSCP, 
single nucleotide substitutions can be identified but the efficiency is between 70 
to 90%. In both techniques, the PCR products mobility on gel is altered in mutant 
sequence as compared to normal sequence and further confirmed by sequencing. 
Once the unknown mutation has been detected by DNA sequencing, these DNA can 
be used as a control to develop ASO and ARMS primer for its detection in further 
cases. The only disadvantage of these techniques is that it cannot be applied to 
hemoglobinopathies.
Heteroduplex analysis is another method utilizes non-denaturing gel elec-
trophoresis. By annealing and amplified target DNA fragment with an amplified 
hetroduplex generator molecule, the unique heteroduplex pattern can be generated 
for each mutation of 130 bases in length [45].
High Resolution Melting (HRM) investigation is a moderately new, post-PCR 
examination technique used to recognize the changes in DNA sequences. The 
technique depends on distinguishing little contrasts in PCR melting (dissociation) 
curves. It is empowered by further developed dsDNA- binding dyes conjunction 
with real-time PCR instrumentation that has exact temperature ramp control and 
Figure 3. 
Gel image shows the multiplex ARMS PCR for five common mutations: [A] IVS 1–5 mutation/normal; [B] 




advanced data capture capabilities. Data are analyzed and manipulated using soft-
ware designed specifically for HRM analysis. The HRM is an analytical platform for 
rapid prenatal and postnatal diagnosis of β-thalassemia common among Southeast 
Asian population. The advantage of HRM is a simple, economical with fast work-
flow platform for the diagnosis of single gene disorder [46, 47].
Multiplex Ligation-Dependent Probe Amplification (MLPA) is versatile 
useful technique for the diagnosis of copy number variations (CNVs) from com-
plete chromosomes to single exons associated with genetic disorders and tumors. 
To detect DNA methylation changes can be detected by Methylation-specific MLPA 
(MS-MLPA) which is sensitive enough to distinguish the changes in disease causing 
genes from highly similar pseudogenes [48].
The multiplex PCR technique that amplify up to 60 probes by using one pair 
of primer. The PCR amplicon with novel genomic target and length are fluores-
cently labeled and identified by capillary electrophoresis. The number of genomic 
sequence of interest is determined by comparing the peak pattern with reference 
sample [49].
Since, the varied molecular basis of α-thalassemia and β- thalassemia mutation 
are uncommon and difficult to detect. In addition to well-established methods, 
MLPA is known as an effective, simple and unambiguous technique for the identifi-
cation and classification of deletions and duplications in thalassemia [48–50].
Direct DNA sequencing is a technique used to identify the specific arrange-
ment of nucleotide bases (A, C, G, and T) in a DNA. The DNA carries the 
information a cell needs to collect protein and RNA atoms. DNA grouping data 
is imperative to researchers examining the elements of qualities. DNA sequence 
information is mandatory to researchers examining the functions of genes [51]. In 
beta globin gene, most of mutations can be identified in two sequence reads but 
for alpha-globin only single read required. The advantage of the simple sequencing 
method for beta globin gene play in important role in prenatal diagnosis where 
the mother is HBS carrier and father is unavailable [52]. If the developing embryo 
found HBS mutation then further analysis of beta globin sequences is must to 
assure that foetus does not have compound heterozygous state HBS and coexisting 
beta-thalassaemia [53].
This is a significant result for the haemoglobinopathies as most cases include 
carrier testing, subsequently arrangement follows much of the time require check-
ing by eye. There are two diverse sequencing sciences accessible dependent on the 
Sanger technique [54–56], dye primer and dye eliminator; they differ from each 
other in the way wherein the fluorescent level is incorporated during linear cycling. 
Despite the fact that the dye eliminator is more straightforward to set-up the signal 
from each nucleotide is less dependable making the dye primer chemistry more 
suitable for heterozygote detection and it is friendlier with sequence analysis pro-
gramming. The dye eliminator would have more application in X- linked diseases, 
for instance, G6PD transformations in which influenced males are hemizygous and 
will show up as a homozygous change. Taking everything together, the way toward 
getting a succession from whole blood and the examination may require 4–5 days, 
with certification using another PCR based test before the change is accounted for. 
The only drawbacks of using sequencing as a routine investigation technique are the 
cost and time taking examination compared to PCR. Sequencing is a multistage pro-
cedure requiring PCR intensification, cycle sequencing and precipitation before the 
sequence can be distinguished. After this the sequence ought to be researched and 
checked and any movements noted. Notwithstanding the grouping examination 
programming is available it is not 100% compelling at identifying heterozygotes.
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Next-generation sequencing (NGS) allow the generation of immense measures 
of genomic data to uncover the genetic constitution of people and to evaluate 
potential health risks. NGS has been commonly utilized for non-invasive prenatal 
diagnosis and novel mutation detection in thalassemia [57, 58].
Microarray analysis procedures are utilized in deciphering the information pro-
duced from probes DNA (Gene chip examination), RNA, and protein microarrays, 
which permit scientist to explore the expression of large number of gene in many 
cases, an organism’s whole genome in a single step experiments. The complemen-
tary sequences will bind to each other. The unknown DNA’s are cut into pieces by 
restriction endonucleases and these DNA pieces are label with fluorescent markers. 
These are then allowed to react with tests of the DNA chip [59–61].
Microarray analysis of gene expression has formed into a great tool for the char-
acterization of various pathophysiological processes. The fundamental idea is that 
RNA isolated from tissue is hybridized to probes for specific genes that are fixed 
in a grid in small microscopic spots. The microarray is a quick, simple to perform, 
and precise strategy for concurrent identification of α and β-thalassemias. But, this 
technique needs should be improved and approved in a bigger number of specimens 
with hemoglobinopathies before further routine laboratory use [62–64].
3.4 Prenatal screening
The prenatal diagnosis based on DNA by amniocentesis and CVS sampling is 
required to detect the genetic abnormalities of the foetus. Now a day’s NIPT is a 
technique to identify the genetic abnormalities of the foetus. This testing examines 
the small remains of foetus DNA that are circulating in a pregnant mother’s blood. 
An appropriate lab conclusion is urgent for describing the various types of thalas-
semia with a significant association for prevention and treatment. Because of 
population migration and mixing of the gene pool of different populations in many 
immigration countries as well as regions the hemoglobiopathies and thalassemia are 
more prevalent over their [65–68].
The importance of prenatal diagnosis comes in the diagnostic field as it helps 
and early diagnoses the growing foetus in the mother wombs for thalassemia 
and hemoglobinopathies. It plays impartment role in the eradication of these 
genetic disorders such as β-thalassemia major, sickle cell disease and hemoglobin 
Bart’s nonimmunehydropsfetalis [69, 70]. The prenatal diagnosis includes the 
investigation of fetal material from chorionic villi, amniotic liquid, string blood, 
and fetal DNA in maternal dissemination. In spite of the way that examination 
of fetal hemoglobin types is successfully performed by means of robotized 
HPLC, it is assessable through assessment of fetal blood got by cordocentesis and 
the technique is inclined to mistake because of mixing of sample by maternal 
tissue [71].
Advances in molecular testing have worked with the assurance of complex 
thalassemias and hemoglobinopathies saw in ethnically varying population. 
Comprehensive screening programs highlighted recognizing carriers and offering 
prenatal diagnosis in pregnancies for thalassemia have been incorporated in Canada 
and European countries [72, 73]. Different procedures have been implimented to 
distinguish thalassemia like genotyping assay, genotyping measur next-generation 
sequencing and mass spectrometry [74–76]. The methods are as yet testing; 
consequently, more investigations are expected to create and approve them and 
eventually lead to proficient, exact and concrete non-invasive prenatal diagnosis of 
thalassemia and hemoglobinopathies [77].
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4. Cost comparison for testing
Low cost techniques High cost techniques
Hematological and
Biochemical Techniques





Molecular Techniques ASO, RDB, MLPA




5. Point of care (POC) testing for thalassemia
As there is a saying that prevention is better than cure. The thalassemia and 
hemoglobinopathies are genetic disorder and due to the migration of population in 
the different regions and endogamy the new combinations of thalassemia hemoglo-
binopaty are arising fast. For the eradication and further treatment and manage-
ment of thalassemia disease an effective diagnostic test at the point of care (POC) is 
the need of hour.
As thalassemia has been spread worldwide an early diagnosis, economical test, 
awareness programmes and prenatal screening will be a milestone for the eradica-
tion of this genetic disorder and to reduce burden of the health sector of a country 
subsequently the economics.
The initial hematological, biochemical screening to the advance molecular 
testing under one roof will not only help to diagnose the thalassemia patients but 
shall be also helpful in the treatment and management of the disease (Figure 1). 
The objective of POC for testing thalassemia will be achieved if these quick test-
ing methods like NESTROFT. This has to be in the approachable distance to the 
patients.
The government should include the thalassemia screening as a mandatory tool 
for screening. The best example Italy and Cyprus there with the initiation of prena-
tal diagnosis and screening of the carrier now this is a thalassemia free country.
Likewise in India, the Uttar Pradesh state government has initiated the task by 
giving free of cost of screening of thalassemia carrier, blood transfusion and iron 
chelators to several medical colleges. The Indian government has provided the 
HPLC machines to provide the screening of the carrier of thalassemia hemoglobin-
opathies. Basically the eradication, treatment and management of thalassemia are 
joint efforts of government, stake holder, policy makers, pediatrician, pathologist, 
transfusion medicine and geneticist.
13
An Early Diagnosis of Thalassemia: A Boon to a Healthy Society
DOI: http://dx.doi.org/10.5772/intechopen.100357
Author details
Nitu Nigam1*, Prithvi Kumar Singh1, Suhasini Bhatnagar2, Sanjay Kumar Nigam3  
and Anil Kumar Tripathi4
1 Department of Centre for Advance Research (Cytogenetics Lab), King George’s 
Medical University, Lucknow, Uttar Pradesh, India
2 RUS Industries, Ghaziabad, Uttar Pradesh, India
3 Department of Pathology, Saraswati Medical College, Unnao, Uttar Pradesh, India
4 Department of Clinical Hematology, King George's Medical University, 
Lucknow, Uttar Pradesh, India
*Address all correspondence to: nigamnitu@gmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
14
Hemodynamics
[1] Old J. Screening and genetic 
diagnosis of hemoglobin disorders. 
Blood Reviews. 2003:43.
[2] Old JM. Screening and genetic 
diagnosis of haemoglobinopathies. 
Scand J Clin Lab Invest. 2006;66:1-16.
[3] Old J, Harteveld CL, 
Traeger-Synodinos J, et al. Prevention of 
Thalassaemias and Other Haemoglobin 
Disorders: Volume 2: Laboratory 
Protocols [Internet]. 2nd edition. 
Nicosia (Cyprus): Thalassaemia 
International Federation; 2012. Chapter 
5, MOLECULAR DIAGNOSIS. Available 
from: https://www.ncbi.nlm.nih.gov/
books/NBK190571
[4] Brown TA. Genomes. 2nd edition. 
Oxford: Wiley-Liss; 2002. Chapter 7, 
Understanding a Genome Sequence. 
Available from: https://www.ncbi.nlm.
nih.gov/books/NBK21136/
[5] Colah RB, Gorakshakar AC. 
Lokeshwar MR, Shah NK, Agarwal B, 
Suchdeva A, editors. Structural 
hemoglobinopathies. IAP speciality series 
on Pediatric Hematolgy and Oncolgy of 
Indian Academy of Pediatrics. 
2006:151–l61.
[6] Ryan K, Bain BJ, Worthington D, 
James J, Plews D, Mason A, et al. 
Significant haemoglobinopathies: 
Guidelines for screening and diagnosis. 
Br J Haematol. 2010;149:35-49.
[7] Nigam N, Kushwaha R, Yadav G, 
Singh PK, Gupta N, Singh B, 
Agrawal M, Chand P, Saxena SK, 
Bhatt MB. A demographic prevalence of 
β Thalassemia carrier and other 
hemoglobinopathies in adolescent of 
Tharu population. J Family Med Prim 
Care 2020;9:4305-4310.
[8] Ghosh K, Colah R, Manglani M, et al. 
Guidelines for screening, diagnosis and 
management of hemoglobinopathies. 
Indian J Hum Genet. 2014;20(2): 
101-119.
[9] Bain BJ. 2nd ed. Oxford: Wiley 
Blackwell; 2006. Hemoglobinopathy 
diagnosis. ISBN: 979 - 1 - 4051-3516-0.
[10] Lewis S, Bain B, Bates I. 10th ed. 
UK: Churchill Livingstone; 2006. Dacie 
and Lewis practical hematology.
[11] Mohanty D, Colah R, editors. 1st ed. 
Mumbai: Bhalani Publishing House; 
2008. Laboratory Manual for screening 
diagnosis and molecular analysis of 
hemoglobinopathies and red cell 
enzymopathies.
[12] Clark BE, Thein SL. Molecular 
diagnosis of haemoglobin disorders. 
Clin Lab Haematol. 2004;26(3):159-176.
[13] Lee YK, Kim HJ, Lee K, Park SH, 
Song SH, Seong MW, Kim M, Han JY. 
Recent progress in laboratory diagnosis 
of thalassemia and hemoglobinopathy: a 
study by the Korean Red Blood Cell 
Disorder Working Party of the Korean 
Society of Hematology. Blood Res. 
2019;54(1):17-22.
[14] Clarke GM, Higgins TN. Laboratory 
investigation of hemoglobinopathies 
and thalassemias: review and update. 
Clin Chem. 2000; 46:1284-1290.
[15] Recommendations of a system for 
identifying abnormal hemoglobins. By 
the International Committee for 
Standardization in Hematology. Blood. 
1978; 52:1065-1067.
[16] Ryan K, Bain BJ, Worthington D, 
et al. Significant haemoglobinopathies: 
guidelines for screening and diagnosis. 
Br J Haematol. 2010; 149:35-49.
[17] Kim SY, Lee SH, Cho SI, et al. 
Molecular identification of the novel 
Gγ-β hybrid hemoglobin: Hb Gγ-β Ulsan 
(Gγ through 13; β from 19). Blood Cells 
Mol Dis. 2010; 45:276-279.
References
15
An Early Diagnosis of Thalassemia: A Boon to a Healthy Society
DOI: http://dx.doi.org/10.5772/intechopen.100357
[18] Mahdieh N, Rabbani B. An overview 
of mutation detection methods in 
genetic disorders. Iran J Pediatr. 
2013;23(4):375-388.
[19] Cao, A., Galanello, R. Beta-
thalassemia. Genet Med 12, 
61-76 (2010).
[20] Thein SL. The molecular basis of 
β-thalassemia. Cold Spring Harb Perspect 
Med. 2013;3(5):a011700. Published 2013 
May 1. doi:10.1101/cshperspect.a011700.
[21] Hardison RC. Evolution of 
hemoglobin and its genes. Cold Spring 
Harb Perspect Med. 2012;2(12):a011627. 
Published 2012 Dec 1. doi:10.1101/
cshperspect.a011627
[22] Huisman T, Carver M, Baysal E, 
Efremov G. A Database of Human 
Hemoglobin Variants and Thalassemias. 
State College, PA: The Pennsylvania 
State University;2013. Accesed 
December, 8, 2018. at http://globin.cse.
psu.edu/cgi-bin/hbvar/query_vars3.
[23] Conner B.J., Reyes A.A., Morin C., 
Itakura K., Teplitz R.L. & Wallace R.B. 
(1983) Detection of sickle cell bs -globin 
allele by hybridization with synthetic 
oligonucleotides. Proceedings of the 
National Academy of Sciences of the 
United States of America 80, 278-282.
[24] Wallace R.B., Johnson M.J., 
Hirose T., Miyake T., Kawashima E.H. & 
Itakura K. (1981) The use of synthetic 
oligonucleotides as hybridization 
probes. II: Hybridisation of 
oligonucleotides of mixed sequence to 
rabbit b-globin DNA. Nucleic Acids 
Research 9, 879-894.
[25] Orkin. S.H.. Sexton, J.P., Cheng. 
T.C.. Goff, S.C.. Giardina, P.V.J. & 
Kazazian. H.H., Jr (1983) TATA box 
transcription mutation in βthalassemia. 
Nucleic Acids Research. 11, 4721-4734.
[26] Pirastu M, Kan YW, Cao A, 
Conner BJ, Teplitz RL, Wallace RB. 
Prenatal diagnosis of beta-thalassemia. 
Detection of a single nucleotide 
mutation in DNA. N Engl J Med. 1983 
Aug 4;309(5):284-287.
[27] Ristaldi M.S., Pirastu M., 
Rosatelli C., Cao A. Prenatal diagnosis 
of β-thalassaemia in Mediterranean 
populations by dot blot analysis with 
DNA amplification and allele specific 
oligonucleotide probes. Prenatal 
Diagnosis. 1989;9:629-638.
[28] Saiki R.K., Walsh P.S., 
Levenson C.H., Erlich H.A. Genetic 
analysis of amplified DNA with 
immobilized sequence-specific 
oligonucleotide probes. Proceedings of 
the National Academy of Sciences, USA. 
1989;86:6230-6234.
[29] Newton C.R., Graham A., 
Heptinstall L.E. Analysis of any point 
mutation in DNA. The amplification 
refractory mutation system (ARMS). 
Nucleic Acids Research. 
1989;17:2503-2516.
[30] Old J.M., Varawalla N.Y, 
Weatherall D.J. The rapid detection and 
prenatal diagnosis of β thalassaemia in 
the Asian Indian and Cypriot 
populations in the UK. Lancet. 
1990;336:834-837.
[31] Old JM, Khan SN, Verma, et al. A 
multi-centre study to further define the 
molecular basis of beta-thalassemia in 
Thailand, Pakistan, Sri Lanka, 
Mauritius, Syria, and India, and to 
develop a simple molecular diagnostic 
strategy by amplification refractory 
mutation system polymerase chain 
reaction. Hemoglobin. 2001;25:397.
[32] Saxena R., Jain P.K., Thomas E, 
Verma I.C. Prenatal diagnosis of 
β-thalassaemia: experience in a 
developing country. Prenatal Diagnosis. 
1998;18:1-7.
[33] Baig SM. Molecular diagnosis of 
beta-thalassemia by multiplex 
Hemodynamics
16
ARMS-PCR: a cost effective method for 
developing countries like Pakistan. 
Prenat Diagn. 2007;27:580-581.
[34] Tan J.A., Tay J.S, Lin L.I., et al. The 
amplification refractory mutation 
system (ARMS): a rapid and direct 
prenatal diagnostic technique for 
β-thalassaemia in Singapore. Prenatal 
Diagnosis. 1994;14:1077-1082.
[35] Ye S, Dhillon S, Ke X, Collins AR, 
Day IN. An efficient procedure for 
genotyping single nucleotide 
polymorphisms. Nucleic Acids Res. 
2001;29(17):E88-e88.
[36] Tan JA, Tay JS, Lin LI, Kham SK, 
Chia JN, Chin TM, Aziz NB, Wong HB. 
The amplification refractory mutation 
system (ARMS): a rapid and direct 
prenatal diagnostic technique for 
beta-thalassaemia in Singapore. Prenat 
Diagn. 1994;14(11):1077-1082.
[37] Linderman R., Hu S.P., Volpato F, 
Trent R.J. Polymerase chain reaction 
(PCR) mutagenesis enabling rapid 
nonradioactive detection of common 
β-thalassaemia mutations in 
Mediterraneans. British Journal of 
Haematology. 1991;1991;78:100-104.
[38] Varawalla NY, Fitches AC, Old JM. 
Analysis of beta-globin gene haplotypes 
in Asian Indians: origin and spread of 
beta-thalassaemia on the Indian 
subcontinent. Hum Genet. 
1992;90:443-449.
[39] Weatherall DJ, Clegg JB. Inherited 
haemoglobin disorders: an increasing 
global health problem. Bull World 
Health Organ. 2001;79(8):704-712.
[40] Faa V., Rosatelli M. C., Sardu R., 
Meloni A., Toffoli C., Cao A. A simple 
electrophoretic procedure for fetal 
diagnosis of b-thalassaemia due to short 
deletions. Prenat Diag. 1992;12:903-908.
[41] Chong S. S., Boehm C. D., Higgs D. 
R., Cutting G. R. Single-tube 
multiplex-PCR screen for common 
deletional determinants of 
α-thalassemia. Blood. 2000;95:360-362.
[42] Liu Y.T., Old J.M., Miles K., 
Fisher C.A., Weatherall D.J. & Clegg J.B. 
Rapid detection of alpha-thalassaemia 
deletions and alpha-globin gene 
triplication by multiplex polymerase 
chain reactions. British Journal of 
Haematology 2000; 108, 295-299.
[43] Losekoot M, Fodde R, Harteveld CL, 
van Heeren H, Giordano PC, Bernini LF. 
Denaturing gradient gel electrophoresis 
and direct sequencing of PCR amplified 
genomic DNA: a rapid and reliable 
diagnostic approach to beta 
thalassaemia. Br J Haematol. 1990 
Oct;76(2):269-274.
[44] Losekoot, M., Fodde, R., Harteveld, 
C. L., van Heeren, H., Giordano, P. C., 
Went, L. N., and Bernini, L. F. (1991). 
Homozygous β+−thalassaemia owing to 
a mutation in the cleavage-
polyadenylation sequence of the human 
β-globin gene. J. Med. Genet. 28:252-255.
[45] Savage, D.A., Wood, N.A., Bidwell, 
J.L., Fitches, A., Old, J.M. & Hui, K.M. 
(1995) Detection of b-thalassaemia 
mutations using DNA heteroduplex 
generator molecules. British Journal of 
Haematology, 90, 564-571.
[46] Pornprasert S, Phusua A, Suanta S, 
et al. Detection of alpha-thalasemia-1 
Southeast Asian type using real-time 
gap-PCR with STBR green1 and high 
resoulution melting analysis. Eur J 
Haematolo. 2008;80(6):510-514.
[47] Prajantasen T, Fucharoen S, 
Fucharoen G. High resolution melting 
analytical platform for rapid prenatal 
and postnatal diagnosis of β-thalassemia 
common among Southeast Asian 
population. Clin Chim Acta. 
2015;441:56-62.
[48] Harteveld Cl, Voskamp A, 
Phylipsen M, et al. Nine unknown 
17
An Early Diagnosis of Thalassemia: A Boon to a Healthy Society
DOI: http://dx.doi.org/10.5772/intechopen.100357
rearrangements in 16p13.3 and 11p15.4 
causing alpha- and beta-thalassaemia 
characterised by high resolution multiplex 
ligation-dependent probe amplification. J 
Med Genet. 2005;42:922-931.
[49] Liu JZ, Han H, Schoulten JP, et al. 
Detection of alpha-thalassemia in China 
by using multiplex ligation-dependent 
probe amplification. Hemoglobin. 
2008;32(6):561-571.
[50] Harteveld CL, Refaldi C, 
Cassinerio E, et al. Segmental 
duplications involving the alpha-globin 
gene cluster are causing beta-thalassemia 
intermedia phenotypes in beta-
thalassemia heterozygous patients. Blood 
Cells Mol Dis. 2008;40(3):312-316.
[51] Koonin EV, Galperin MY. Sequence - 
Evolution - Function: Computational 
Approaches in Comparative Genomics. 
Boston: Kluwer Academic; 2003. Chapter 
Principles and Methods of Sequence 
Analysis. Available from: https://www.
ncbi.nlm.nih.gov/books/NBK20261/
[52] Fakher R, Bijan K, Taghi AM. 
Application of diagnostic methods and 
molecular diagnosis of hemoglobin 
disorders in Khuzestan province of Iran. 
Indian J Hum Genet. 2007;13(1):5-15. 
doi:10.4103/0971-6866.32028
[53] Bajwa H, Basit H. Thalassemia. 
[Updated 2021 Jan 24]. In: StatPearls 
[Internet]. Treasure Island (FL): 
StatPearls Publishing; 2021 Jan-. 
Available from: https://www.ncbi.nlm.
nih.gov/books/NBK545151/.\
[54] Sanger F, Donelson JE, Coulson AR, 
Kössel H, Fischer D. Use of DNA 
polymerase I primed by a synthetic 
oligonucleotide to determine a nucleotide 
sequence in phage fl DNA. Proc Natl 
Acad Sci U S A. 1973;70(4):1209-1213.
[55] Sanger F, Nicklen S, Coulson AR. 
DNA sequencing with chain-
terminating inhibitors. Proc Natl Acad 
Sci U S A. 1977;74(12):5463-5467.
[56] Bwayo D, Kaddumukasa M, 
Ddungu H, Kironde F. Prevalence of 
glucose-6-phosphate dehydrogenase 
deficiency and its association with 
Plasmodium falciparum infection 
among children in Iganga distric in 
Uganda. BMC Res Notes. 2014 Jun 
18;7:372.
[57] Papasavva T, van Ijcken WF, 
Kockx CE, et al. Next generation 
sequencing of SNPs for non-invasive 
prenatal diagnosis: challenges and 
feasibility as illustrated by an 
application to β-thalassaemia. Eur J 
Hum Genet 2013;21:1403-1410.
[58] Xiong L, Barrett AN, Hua R, et al. 
Non-invasive prenatal diagnostic testing 
for β-thalassaemia using cell-free fetal 
DNA and next generation sequencing. 
Prenat Diagn 2015;35:258-265.
[59] Zesong L, Ruijun G, Wen Z. Rapid 
detection of deletional alpha-
thalassemia by an oligonucleotide 
microarray. American journal of 
Hematology. 2005;80:306-308.
[60] Bang-Ce Y, Hongqiong L, 
Zhuanfong Z, et al. Simultaneous 
detection of alpha-thalassemia and 
beta-thalassemia by oligonucleotide 
microarray. Haematologica. 
2004;89:1010-1012.
[61] Gemignani F, Perra C, Landi S, et al. 
Reliable detection of beta-thalassemia 
and G6PD mutations by a DNA 
microarray. Clinical Chemistry. 
2002;48:2051-2054.
[62] Van Moorsel CH, van 
Wijngaraarden EE, Fokkema IF, et al. 
beta-Globin mutation detection by tagged 
single-base extension and hybridization 
to universal glass and flow-through 
microarrays. European Journal Human 
Genetics. 2004;12:567-573.
[63] Lu Y, Kham SK, Tan PL, et al. 
Arrayed primer extension: a robust and 
reliable genotyping platform for the 
Hemodynamics
18
diagnosis of single gene disorders: 
beta-thalassemia and thiopurine 
methyltransferase deficiency. Genet 
Test. 2005;9:212-219.
[64] Cremonesi L, Ferrari M, 
Giordano PC, et al. An overview of 
current microarray-based human globin 
gene mutation detection methods. 
Hemoglobin. 2007;31(3):289-311.
[65] Sayani FA, Kwiatkowski JL. 
Increasing prevalence of thalassemia in 
America: implications for primary care. 
Ann Med. 2015;47:592-604.
[66] Anwar WA, Khyatti M, 
Hemminki K. Consanguinity and 
genetic diseases in North Africa and 
immigrants to Europe. Eur J Public 
Health. 2014;24(Suppl 1):57-63.
[67] Jahng J, Yoon KH. A family with a 
hemoglobin E variant including a Thai 
immigrant woman in Korea. Ann Lab 
Med. 2017;37:71-73.
[68] Lee HS, Lee DY, Kim HJ, Lee IS. Two 
cases of alpha-thalassemia in Korean 
children from multicultural family. Clin 
Pediatr Hematol Oncol. 2011;18:136-139.
[69] Li DZ, Yang YD. Invasive prenatal 
diagnosis of fetal thalassemia. Best Pract 
Res Clin Obstet Gynaecol. 2017;39:41-52.
[70] 27.Seale TW, Rennert OM. Prenatal 
diagnosis of thalassemias and 
hemoglobinopathies. Ann Clin Lab Sci. 
1980;10:383-394.
[71] Sanguansermsri T, 
Thanaratanakorn P, Steger HF, et al. 
Prenatal diagnosis of hemoglobin Bart's 
hydrops fetalis by HPLC analysis of 
hemoglobin in fetal blood samples. 
Southeast Asian J Trop Med Public 
Health. 2001;32:180-185.
[72] Cousens NE, Gaff CL, Metcalfe SA, 
Delatycki MB. Carrier screening for 
beta-thalassaemia: a review of 
international practice. Eur J Hum Genet. 
2010;18:1077-1083.
[73] Langlois S, Ford JC, Chitayat D 
CCMG Prenatal Diagnosis Committee; 
SOGC Genetics Committee. Carrier 
screening for thalassemia and 
hemoglobinopathies in Canada. J Obstet 
Gynaecol Can. 2008;30:950-959.
[74] Papasavva T, van Ijcken WF, 
Kockx CE, et al. Next generation 
sequencing of SNPs for non-invasive 
prenatal diagnosis: challenges and 
feasibility as illustrated by an 
application to β-thalassaemia. Eur J 
Hum Genet. 2013;21:1403-1410.
[75] Li Y, Di Naro E, Vitucci A, et al. Size 
fractionation of cell-free DNA in 
maternal plasma improves the detection 
of a paternally inherited beta-
thalassemia point mutation by MALDI-
TOF mass spectrometry. Fetal Diagn 
Ther. 2009;25:246-249.
[76] Breveglieri G, Travan A, D'Aversa E, 
et al. Postnatal and non-invasive 
prenatal detection of β-thalassemia 
mutations based on Taqman genotyping 
assays. PLoS One. 2017;12:e0172756.
[77] Zafari M, Kosaryan M, Gill P, et al. 
Non-invasive prenatal diagnosis of 
β-thalassemia by detection of the 
cell-free fetal DNA in maternal 
circulation: a systematic review and 
meta-analysis. Ann Hematol. 
2016;95:1341-1350.
